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Abstract
Antiplatelet therapy constitutes a cornerstone in the strategies aimed at the effective management 
of acute coronary syndrome. Abciximab is the oldest and most commonly used intravenous antipla-
telet agent in this context, in particular when an invasive strategy is adopted. It is very commonly 
used in more unstable and high-risk patients. Trials have proven the event-free survival benefits of 
using abciximab in the right context. This agent also has some adverse outcomes associated with its 
use that the clinicians need to be well aware of and take precautions against. The comparative cost 
efficacy with its use too is of significance. There is a growing evidence base on the different ways 
abciximab is used and the benefits and risks thereof. Since the development and introduction of no-
vel anticoagulants and more potent oral anti-platelet agents, the place of abciximab in the treatment 
of acute coronary syndrome today needs to be reviewed and clearly defined. This review attempts to 
study the cross-section of the evidence base to date on the clinical use, efficacy and risks related to 
the use of abciximab and spotlight the most recent guidelines published by the different global peak 
bodies to provide a practical overview to the clinician.
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Introduction
Abciximab is a very commonly used intravenous glycoprotein (GP) IIb/IIIa inhibitor in current car-
diovascular therapeutics. GP IIb/IIIa inhibitors are potent intravenous antiplatelet agents that came to 
prominence in the 1990s for their use in acute coronary syndromes (ACS) and percutaneous coronary 
intervention (PCI). GP IIb/IIIa inhibitors were created for use as a part of dual anti-platelet strategy 
in combination with acetyl salicylic acid (aspirin) prior to the wide use of thienopyridines and cyclo-
pentyltriazolopyrimidine agents (clopidogrel, prasugrel, ticagrelor). Abciximab, the first such agent 
approved by the FDA in 1994, was discovered by Centocor BV and Eli Lilly Incorporated, and has since 
been distributed under the trade name Reopro®.
Abciximab is a monoclonal antibody directed against the glycoprotein IIb/IIIa receptor present on 
platelets and inhibits cross-linking and platelet aggregation. It is created from the fragment antigen-
binding (Fab) section of an immunoglobulin and directly targets the platelet membrane where it anta-
gonises the GP IIb/IIIa receptor.
The goals of therapy with this type of agent are to prevent thrombus propagation and re-occlusion in 
diseased vessels due to excessive platelet reactivity and thereby aid in revascularisation. Abciximab is 
often used in the setting of PCI as the action of angioplasty and stenting is known to cause endothelial 
damage and GP IIb/IIIa activation.
Molecular mechanism: the pharmacodynamics 
and pharmacokinetics of abciximab
Platelet aggregation is an imperative mechanism by which acute coronary syndrome is triggered and 
a key target for pharmacotherapy in the treatment of ischaemic heart disease, especially in the acute 
setting. The surface of the platelet has many mechanisms that contribute to adhesion, aggregation and 
thrombus formation. One of the most important means by which this occurs is the GP IIb/IIIa recep-
tor, which is regarded as highly platelet specific and present in high frequency (~80,000 copies per 
platelet) on each platelet. When a platelet becomes activated, either by endothelial damage or other 
similar mechanisms, intracellular pathways cause the GP IIb/IIIa receptor to undergo a conformational 
change that alters its state from one of low to high affinity [1,2]. Once this takes place, the GP IIb/IIIa 
receptor is free to bind adhesive molecules such as von Willebrand factor and fibrinogen causing cross-
linkage between platelet surfaces and subsequent aggregation. Abciximab works to prevent binding of 
adhesive molecules to the GP IIb/IIIa receptor, which is the sole mechanism available for the formation 
of cross-linked platelets and thus prevent further platelet aggregation. When the GP IIb/IIIa receptor 
is either partially or completely blocked total suppression of platelet aggregation is possible with these 
agents [3]. Abciximab has also been shown to bind with comparable efficacy to both latent and activa-
ted platelet receptors and this further enhances its antiplatelet effect [2].
In order for effective antiplatelet activity to take place >80% of target receptors need to be occupied 
by the GP IIb/IIIa inhibitor. At 50% occupancy patients may still have close to normal platelet aggre-
gation. High dose bolus abciximab (0.25 mg/kg) has been shown to cause ≥80% receptor occupancy 
within 2 hours of administration and therefore complete inhibition of platelet aggregation. After bolus 
injection abciximab has a short first phase half-life of around 10 minutes with rapidly decreasing pla-
sma levels. A second phase half-life of around 30 minutes follows and this is thought to be due to the 
initial occupation and binding of GP IIb/IIIa receptors by the bolus dose. The metabolism of abciximab 
is due to degradation by proteolysis that occurs in the kidney [2,3]. The effect of bolus abciximab can be 
perpetuated by a continuous infusion at 0.125 µg/kg/min (to a maximum of 10 µg/minute).
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Upon cessation of abciximab therapy the plasma level drops steeply over 6 hours and thereafter decre-
ases at a much slower rate. Platelet function generally recovers within 48 hours even though low-level 
receptor blockade can still be present at 10 days and the drug may remain in the circulation for up to 15 
days. Recovery of platelet function is independent of the modality of administration.
Indications
The initial approval for the use of abciximab was for percutaneous coronary intervention (PCI) and was 
aimed at preventing cardiac ischaemia and its complications during such procedures. Since this time 
the indication for the use of GP IIb/IIIa inhibitors has expanded to include other acute coronary syn-
dromes and also occasionally, stable ischaemic heart disease. Abciximab was the first such agent used 
in clinical practice and traditionally is utilised in patients with elevated troponin, high thrombus load 
on coronary angiography or other high-risk features such as dynamic ECG changes and resistant chest 
pain. All early clinical trials used these agents in combination with aspirin and unfractionated heparin; 
therefore today this remains the intended regime of choice when using abciximab.
Efficacy & evidence from pivotal trials
During the mid to late 1990s abciximab and the other GP IIb/IIIa inhibitors were subject to extensive 
study to elicit the true potential benefit of these agents in the treatment of acute coronary syndromes. 
These early trials utilised GP IIb/IIIa inhibitors as a secondary agent for its potent antiplatelet effect in 
combination with aspirin and took place before the advent of dual oral antiplatelet therapy with thie-
nopyridines such as clopidogrel. Routine insertion of coronary stents was also not commonplace in 
the setting of PCI and ACS at this time. These early trials assisted in confirming the theory that potent 
inhibition of platelet aggregation would lead to improved clinical outcomes and lower mortality.
The EPIC and EPILOG trials were two of the first large clinical trials to investigate the efficacy of abcixi-
mab in PCI [4-6]. The EPIC trial administered abciximab as a bolus and 12-hour infusion to patients 
treated with coronary angioplasty or atherectomy who were deemed high risk for complications of 
their underlying cardiac disease. This included patients with unstable angina (UA), evolving or recent 
acute myocardial infarction (AMI) or adverse coronary morphology. The study demonstrated that pa-
tients receiving abciximab therapy showed a significant reduction in the incidence of 30-day mortality 
and morbidity in the form of AMI or need for revascularisation (12.8% versus 8.3% with a 35% relative 
risk reduction). This benefit was found to extend out to 6 months and 3 years on follow-up. The EPI-
LOG trial extended the use of abciximab therapy to patients with lower risk profiles and was ceased 
early due to the experimental arms of the study exceeding predetermined superiority levels. This trial 
demonstrated that the use of abciximab in PCI with low dose or standard dose, weight-adjusted he-
parin did not carry any significant increase in bleeding complications whilst contributing to superior 
mortality and morbidity outcomes compared to heparin alone, especially when used in conjunction 
with early vascular sheath removal and elimination of routine post procedural heparinisation. A com-
bined analysis of the results from the EPIC and EPILOG studies together demonstrated a significant 
reduction in 30-day death and AMI in patients receiving abciximab (19.9% vs. 8.4%, p = 0.008) and this 
benefit persisted out to 6 months.
The EPISTENT study looked into the comparative efficacy of abciximab in the setting of coronary 
intervention with stenting and coronary intervention with balloon angioplasty alone in comparison 
to stenting with placebo. There were significant reductions in the 30-day composite of death, revascu-
larisation and MI in the abciximab arms [7]. This study proved the case for the use of abciximab with 
stenting for superior event-free survival in patients undergoing PCI.
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The CAPTURE trial extended the potential value of GP IIb/IIIa inhibitors by demonstrating its effi-
cacy in patients with refractory unstable angina [5,8]. Patients receiving abciximab had lower rates of 
AMI prior to and during percutaneous trans luminal coronary angioplasty (PTCA) and also achieved 
the primary composite endpoint of decreased all-cause mortality, AMI or revascularisation at 30 days 
(11.3% vs. 15.9 %, p = 0.012). The CAPTURE trial demonstrated that the use of 18 to 24-hour pre-pro-
cedural abciximab infusion was effective at stabilising patients with ACS whilst improving the safety of 
PCTA and reducing early ischaemic events.
A meta-analysis of the RAPPORT, ADMIRAL, ISAR-2, CADILLAC and ACE trials was performed to 
investigate the efficacy of abciximab in PCI and stenting fo AMI [9]. This meta-analysis showed that 
abciximab was effective in reducing early mortality at 30 days compared to placebo (2.4 % vs. 3.4%) and 
that this benefit extended out to 6 and 12 months on follow up. Rates of re-infarction with abciximab 
therapy were also lower at 30 days (1.0% vs. 1.9%) and there was no significant increase in bleeding 
with the use of a GP IIb/IIIa inhibitor.
In the year 2000 a pooled analysis of 21 trials was performed to evaluate the use of GP IIb/IIIa inhibitors 
in a variety of clinical settings including ST segment elevation myocardial infarction (STEMI), Non-
ST segment elevation myocardial infarction (NSTEMI) and ACS undergoing PCI [10]. This analysis 
incorporated close to 50,000 patients who had been enrolled in randomised control trials up until that 
time. GP IIb/IIIa inhibitors were shown to significantly reduce the combined endpoint of 30-day death, 
nonfatal AMI or urgent revascularisation in patients with STEMI (3.9% vs. 7.8%), NSTEMI (11.4% vs. 
12.8%), and collectively those undergoing PCI (7.8% vs. 11.6%).
The BRAVE-3 trial was aimed at determining the efficacy of abciximab therapy prior to PCI in patients 
who had received dual oral antiplatelet therapy with aspirin and a loading dose of 600 mg clopidogrel 
[11]. Early positive trials in the use of GP IIb/IIIa inhibitors were prior to routine loading of clopidogrel 
so this study was intended to address abciximab use in conjunction with the now commonplace use of 
thienopyridines in patients receiving PCI. In this trial 800 patients who presented within 24 hours of 
STEMI were loaded with clopidogrel and transferred to an intensive care unit (ICU) prior to primary 
PCI. In ICU the patients were randomised to either intravenous abciximab infusion or placebo in a 
double-blinded manner and treated for 12 hours prior to PCI. Results demonstrated no significant 
change in infarct size as measured by single-photon emission computed tomography and there was no 
improvement in the rates of 30 day mortality or recurrent AMI. Both study-groups had equivalent rates 
of bleeding complications. The main detractor from this study was the upstream (prior to catheterisa-
tion) use of abciximab, which (as discussed later) has been shown to be of questionable benefit when 
compared to downstream administration (within the cardiac catheter laboratory).
Use of glycoprotein IIb/IIIa inhibitors 
in conjunction with thrombolysis
The role of GP IIb/IIIa inhibitor treatment in conjunction with thrombolysis in STEMI was investiga-
ted prior to the routine use of dual oral anti-platelet therapy with two large randomised trials, GUSTO 
V and ASSENT-3.
GUSTO V was a study involving 16,588 patients randomised to either full-dose thrombolysis with 
reteplase versus half-dose reteplase and full dose abciximab therapy [12]. Overall results showed no 
statistical difference in the primary end point of 30-day mortality. Patients who received combination 
treatment did have a lower incidence of re-infarction and recurrent ischaemia within 7 days but this 
was at the cost of more bleeding complications. Patients from the combination arm had significantly 
more thrombocytopaenia, bleeding and requirement for transfusion (p<0.0001), this was particularly 
relevant in patients over 75 years of age.
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ASSENT-3 was a similar large trial, which published comparable results around the same time as 
GUSTO V [13]. It involved the randomisation of 6095 patients to one of three groups:
 • full-dose tenecteplase and therapeutic dose enoxaparin;
 • full-dose tenecteplase and unfractionated heparin;
 • half-dose tenecteplase, unfractionated heparin and 12-hour infusion of abciximab.
The investigators found no significant difference in the 30-day mortality rates between the three arms, 
but there was an increased risk of bleeding and transfusion requirement in the abciximab arm. Si-
milar to GUSTO V, this trial also demonstrated increased risk of overall bleeding specifically in the 
abciximab arm with a further increased propensity for complications in patients over 75 years of age, 
including intracranial haemorrhage.
The more recent (2007) FINESSE study compared primary PCI with abciximab in the catheterisation 
laboratory, facilitated PCI with upstream abciximab and facilitated PCI with upstream abciximab and 
reteplase [14]. 1693 patients were randomised to the three arms of the study. Results showed that com-
bination therapy did not demonstrate any clinical benefit in all-cause mortality or complications from 
AMI. TIMI major and minor bleeding was significantly increased in the two arms of facilitated PCI 
compared to primary PCI (14.5% vs. 10.1% vs. 6.9%, respectively).
Given the data currently available, routine use of GP IIb/IIIa inhibitors in conjunction with throm-
bolysis is not recommended and may lead to significant bleeding complications, especially in the el-
derly population.
Complications and safety
The major safety issues that surround abciximab are with regards to its associated risk of thrombocyto-
paenia, significant bleeding and possible drug allergy.
Thrombocytopaenia
The finding of a low platelet count with the use of GP IIb/IIIa inhibitors is a common adverse event and 
usually presents in one of the two following ways:
 • pseudothrombocytopaenia due to testing artefact or
 • true thrombocytopaenia as an immune mediated phenomenon.
Pseudothrombocytopaenia refers to a laboratory artefact due to the clumping of platelets usually in the 
presence of EDTA anti-coagulant common to the blood tubes used during collection. In a review of 
four large trials involving the use of abciximab the incidence of pseudothrombocytopaenia was found 
to be 2% overall which accounted for over one third (36%) of all thrombocytopaenia involved in the 
use of abciximab [15]. Patients diagnosed with pseudothrombocytopaenia were found to have no as-
sociated adverse clinical outcomes.
A clear association has been found between the use of all GP IIb/IIIa inhibitors and clinically signifi-
cant true thrombocytopaenia. This adverse outcome, which at times may be quite profound, usually 
occurs within the first 24 hours but has been noted to occur as early as 30 minutes to several hours 
post administration [16-19]. This phenomenon has been found to be independent of heparin induced 
thrombocytopaenia (HIT) that caused early contention as both agents are commonly used in conjun-
ction. Thrombocytopaenia from GP IIb/IIIa inhibitors has been found to be rapid and at times severe 
in nature with platelet counts under 30,000 per µl whilst HIT is usually of more slow progression and 
onset with a less significant drop in platelet numbers [20].
The mechanism of this rapid fall in platelets is thought to be auto-immune in nature and related to an-
tibodies targeting the murine peptide sequences incorporated into the Fab fragment of the monoclonal 
antibody abciximab once it has interacted with the GP IIb/IIIa receptor [21].
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A pooled analysis was performed to evaluate the significance of thrombocytopaenia associated with 
the use of GP IIb/IIIa inhibitors. Eight randomised control trials were reviewed and it was found that 
abciximab increased the incidence of both mild (4.2% vs. 2%) and severe thrombocytopaenia (1% vs. 
0.4%) as compared to placebo [18].
The TARGET trial revealed that thrombocytopaenia was an adverse event more common to abciximab 
(2.4%) than tirofiban (0.5%) [19]. It also revealed that those patients who suffered from thrombocyto-
paenia had an increased incidence of severe bleeding (5.1 versus 0.7%), required more blood transfu-
sion (6.1 versus 1.4%) and suffered higher rates of 30-day mortality, myocardial infarction or needed 
more revascularisation (12.2% vs. 6.6%).
Management of thrombocytopaenia associated with GP IIb/IIIa inhibitors requires regular monitoring 
of platelet levels and thereby earlier detection. It is reasonable to obtain platelet counts on such patients 
prior to treatment; 2-4 hours post bolus injection, daily during therapy and prior to discharge [17]. If a 
drop in the platelet count of >75% of pre-treatment level or below 100,000 per µl is documented then 
further management should involve:
 • ruling out pseudothrombocytopaenia with a peripheral blood smear looking for platelet clumping;
 • cessation of the GP IIb/IIIa infusion;
 • exclusion of other possible cause of low platelet count including HIT;
 • platelet transfusion may be considered in the presence of severe bleeding, platelet count <10,000 
per µl or if an emergency invasive procedure is required.
Re-administration of abciximab to patients with documented GP IIb/IIIa induced thrombocytopaenia 
is not recommended as it has been found to carry a high risk of recurrent and often more significant 
thrombocytopenia. An incidence around 2.4% of platelet counts below 20,000 per µl was noted on one 
study and it was as high as 12% if the second exposure was within 2 weeks from the initial administra-
tion [22,23].
Bleeding
Given the nature of its antiplatelet action and with its utilisation most commonly in the setting of other 
anticoagulant agents, bleeding is a significant concern with the use of GP IIb/IIIa inhibitors.
Early studies in the use of GP IIb/IIIa inhibitors, prior to the introduction of dual oral antiplatelet 
therapy, had conflicting results with regards to incidence of bleeding in comparison to placebo. Some 
studies showed a higher incidence of statistically and clinically significant bleeding [24,25] while others 
were more equivocal [26-28]. Overall these randomised control trials demonstrated that abciximab can 
increase the bleeding risk by up to 7% in comparison to placebo.
The ISAR-REACT 2 trial was a study involving 2022 patients who received pre-treatment with aspirin 
and 600 mg clopidogrel prior to PCI[29]. This study did not reveal a statistically significant difference 
in the rates of bleeding between patients receiving abciximab versus placebo (4.5% and 4.0% respecti-
vely).
With regards to the specific complication of intracerebral haemorrhage (ICH), a pooled analysis of 14 
randomised trials was performed looking at 28,000 patients who either received a GP IIb/IIIa inhibi-
tor or placebo [30]. The incidence of ICH with the use of GP IIb/IIIa inhibitor and heparin was not 
statistically different to heparin together with placebo (0.12% vs. 0.09%, odds ratio 1.3) and there was 
no difference between the use of a GP IIb/IIIa inhibitor or heparin as the sole agent (0.07% vs. 0.06%).
Allergy
Although an antibody response to the monoclonal abciximab has been theorised to cause a sub type of 
immune mediated thrombocytopaenia in clinical use, there has been no increased evidence of allergic 
reactions or anaphylaxis in its use whether as single bolus or recurrent infusions [22,23].
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Safety related to coronary artery bypass graft (CABG) surgery
Emergency CABG after recent infusion of abciximab with PCI has been associated with increased risk 
of bleeding complications and increased mortality [31]. This risk is substantially increased if the drug 
is discontinued within 6 hours of the operation and is thought to be due to the extended antiplatelet 
effect elicited by abciximab. The risk of peri-operative complications seems largely dependent on the 
interval between abciximab cessation and surgery. Studies involving patients receiving CABG more 
than 2-hours post abciximab infusion were not found to have a significant increase in blood transfu-
sion although requirement for platelet infusion was more common [32-34]. Evidence of significant 
bleeding events become much more prominent with emergency CABG operations occurring under 
24 hours post cessation of abciximab. Patients were found to need up to 6 units of packed red cells and 
20-30 units of platelets and 4-8 units of fresh frozen plasma peri-operatively [35,36]. These studies have 
delivered differing results with regards to the increase in peri-operative mortality.
In summary, recent abciximab infusion is not a contra-indication to urgent CABG but measures 
should be taken to delay the operation where possible. If emergency bypass surgery is required within 
12-24 hours of abciximab infusion, a high level of caution should be exercised and supportive measures 
should be put in place to prevent or treat excessive bleeding.
Comparison with eptifibatide
Eptifibatide is a synthetic cyclic heptapeptide antagonist of GP IIb/IIIa which was discovered by COR 
Therapeutics and Schering Plough and approved by the FDA four years after abciximab, in 1998. Eptifi-
batide is produced under the trade name Integrilin® and was discovered in the venom of the American 
southeastern pygmy rattlesnake during a search of snake venoms with the potential to inhibit the GP 
IIb/IIIa receptor. Eptifibatide is used in patients undergoing PCI in the setting of ACS and sometimes 
for stable coronary disease. It is used to reduce the risk of morbidity and mortality due to thrombotic 
complications.
As opposed to abciximab, eptifibatide has a much lower affinity in binding the GP IIb/IIIa receptor and 
thus has a much shorter plasma half-life of approximately 1.5 to 2 hours. Due to this increased clearan-
ce, restoration of normal haemostatic function can be obtained within 3-4 hours of infusion cessation. 
Eptifibatide is primarily cleared by the kidneys (~98%) and thus is relatively contra-indicated in renal 
impairment. It may still be utilised in this subset of patients but requires halving of dosage in moderate 
to severe renal impairment (creatinine clearance <50 ml/min using the Cockcroft-Gault formula) and 
is contra-indicated in haemodialysis patients due to lack of trial data.
Due to the similar mechanism of action between abciximab and eptifibatide (and also the similar non-
peptide inhibitor tirofiban), many trials have looked for variance between the agents with regards to 
patient outcome and adverse effects.
In 2010, a retrospective analysis of the Swedish Coronary Angiography and Angioplasty Registry 
(SCAAR) was performed involving 11,479 patients between 2004-2007 who underwent primary PCI 
and received either abciximab or eptifibatide. The primary endpoint was death or myocardial infarc-
tion during 1-year follow-up in an effort to test non-inferiority of the newer agent, eptifibatide. The 
results of the multivariate analysis confirmed non-inferiority in the primary endpoint as well as the 
secondary endpoints of death and MI individually, thus suggesting that either drug is appropriate in 
this setting [37].
That same year the results of the Eptifibatide versus Abciximab (EVA-AMI) Trial also concluded eptifiba-
tide was as effective as abciximab as an adjunct to primary PCI with respect to ST segment resolution [38].
Two separate meta-analyses of randomised trials were completed in 2009 comparing the use of abcixi-
mab versus small-molecule GP IIb/IIIa inhibitors (either tirofiban or eptifibatide) in STEMI patients 
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undergoing PCI [39,40]. Both analyses showed no significant difference in clinical outcomes or com-
plications. There was no statistically significant difference in rates of 30-days mortality, re-infarction or 
major bleeding. These results were sustained up to 8 months post procedure.
Specifically with regards to rates of stent thrombosis post PCI, results from the HORIZONS-AMI Trial 
were presented in 2009 [41] which revealed no significant difference between the two GP IIb/IIIa inhi-
bitors up to 1 year of follow up, suggesting that eptifibatide has equivalent incidence of stent thrombo-
sis compared to abciximab (3.6% versus 2.8%, p = 0.93).
Given the above studies, either agent is considered acceptable in the invasive management of acute 
coronary syndromes and has been proven to have similar rates of positive outcome and complications. 
Being the first glycoprotein IIb/IIIa inhibitor made available for clinical use, abciximab has the largest 
volume of data related to its safety and efficacy (including in those with renal impairment). However a 
cost-analysis published by Jayasinghe et al. revealed that eptifibatide may be significantly more econo-
mical than abciximab when used in the setting of invasive management of STEMI [42].
Comparison with bivalirudin
Bivalirudin is a novel anticoagulant which has recently begun to feature prominently in global cardiac 
guidelines due to recent study data. It is a potent and highly specific short synthetic peptide that is a re-
versible direct inhibitor of thrombin. Bivalirudin has a quick onset of action and short half-life and does 
not carry the risk of thrombocytopaenia. Given that it does not bind plasma proteins or red cells, bivali-
rudin has a predictable and reproducible antithrombotic response, which makes it a very suitable alterna-
tive to heparin therapy. Bivalirudin has been the subject of many recent studies and analyses with regards 
to its use in acute coronary syndromes, usually in comparison to heparin +/- GP IIb/IIIa inhibitors.
HORIZONS-AMI was a large prospective, multicentre randomised trial in STEMI patients undergoing 
primary PCI comparing bivalirudin monotherapy to heparin plus GP IIb/IIIa inhibitor [43,-45]. It sho-
wed a significant decrease in the incidence of net adverse events (9.2% vs. 12.1%) and major bleeding 
(4.9% vs. 8.4%) in the bivalirudin group at 30 days, and these benefits were shown to persist out to 2 
years of follow-up. The rate of early stent thrombosis (< 24hours) was increased by 1% with bivalirudin 
alone (p<0.05) but the overall rate was similar on further follow-up, from 30 days to 2 years.
A pooled analysis of two similar trials (ACUITY & ISAR-REACT 4) in the treatment of non-ST seg-
ment elevation myocardial infarction revealed similar results of no significant rise of net adverse events 
at 30 days and that bivalirudin alone was superior in reducing the incidence of bleeding events when 
compared to the combination heparin and GP IIb/IIIa strategy [46].
The REPLACE-2 multicentre randomised trial also showed significant reduction in major bleeding 
with bivalirudin monotherapy versus heparin plus GP IIb/IIIa inhibitor (2.4 vs. 4.1%) and also a 24% 
risk reduction of death that sustained up to 12 months [47].
Due to recent positive results in the use of bivalirudin for both STEMI and NSTEMI coronary syn-
dromes it is now recommended in both the European Cardiac Society (ESC) and American College 
of Cardiology/American Heart Association (ACC/AHA) guidelines for use as a sole anticoagulation 
agent with PCI. It may prove especially useful in those with elevated bleeding risk and the option of 
bailout with GP IIb/IIIa inhibitors in high-risk patients still remains a safe option with this strategy.
Intracoronary vs. intravenous administration
Some debate has surrounded the intra-coronary use of abciximab and other GP IIb/IIIa inhibitors 
versus the standard of care, which is intravenous administration. Early trials using these two methods 
were of high quality but small in nature and demonstrated varied results.
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Two meta-analyses were published in 2012 with differing results but came to an agreement on the 
suspected role of intra-coronary GP IIb/IIIa inhibitors. The first study by Shimada et al. showed a 
significant reduction in mortality with intra-coronary use of abciximab (1.5% vs. 3.6%, p = 0.04) [48]. 
In comparison De Luca et al. completed a meta-analysis of 8 randomised control trials that revealed 
significant improvement in myocardial perfusion but with no significant benefit to mortality [49].
The recently published AIDA STEMI study was the first large prospective randomised control trial to 
compare intracoronary administration and systemic administration of GP IIb/IIIa in STEMI. This trial 
looked at 2065 patients undergoing PCI for STEMI. Results of the study showed no significant differen-
ce in the primary endpoint, the composite of mortality, new MI and new heart failure at 90 days [50].
Given the research to date, intracoronary administration of GP IIb/IIIa inhibitors remains a viable 
alternative in the treatment of acute coronary syndromes but has not yet been proven superior to syste-
mic administration. Theoretically intra-coronary administration may perhaps be safer than systemic 
administration in the setting of high bleeding-risk.
TRIAL Method Outcomes References
EPIC
1995
n = 1362 
Abciximab therapy vs placebo 
in high risk patients undergoing 
coronary intervention
Abciximab reduced 30 day death and recurrent AMI
Results trended out to 6 months follow-up
[4,5]
EPILOG
1998
n = 2792
Abciximab plus either standard 
or low dose heparin vs. standard 
dose heparin and placebo during 
coronary intervention
Significant reduction in 30 day mortality and AMI 
requiring trial to be stopped
Bleeding incidence equivalent to placebo
[5,6]
EPISTENT
1998
n = 2399
Stenting and placebo vs stenting 
and abciximab vs. angioplasty 
and abciximab during coronary 
intervention
Significant decrease in death and large AMI with the 
use of abciximab
Balloon angioplasty with abciximab is safer than 
stenting without abciximab
Less bleeding with the use of abciximab
[7]
CAPTURE
1997
n = 1265
Bolus and infusion abciximab vs. 
placebo for refractory unstable 
angina going for PTCA
Trial stopped early due to positive results
Significantly reduced 30 day mortality, AMI, 
revascularisation
Low rates of bleeding
[5,8]
BRAVE-3
2009
n = 800 
Upstream abciximab vs. placebo in 
STEMI, used in conjunction with 
dual antiplatelet therapy
No reduction in infarct size on sestamibi scanning 
with addition of abciximab to aspirin plus 
clopidogrel
[11]
GUSTO V
2001
n = 16,588
Half-dose reteplase and abciximab 
vs. full-dose reteplase in STEMI
Non-inferiority of reteplase and abciximab but no 
significant reduction in mortality
[12]
ASSENT-3
2001
n = 6095
Full-dose tenecteplase and 
enoxaparin vs. half-dose tenecteplase 
and UFH and abciximab vs. full-dose 
tenecteplase and UFH in AMI
Reduced complications of AMI with both 
enoxaparin and abciximab regimes
Enoxaparin and tenecteplase demonstrated the 
most significant decrease in 30 days mortality
[13]
FINESSE
2008
n = 2452
Reduced dose reteplase and 
abciximab vs. abciximab alone vs. 
placebo in STEMI with delay to 
PCI
No significant difference in outcome between study 
arms
Trend toward better outcome with abciximab and 
reteplase in anterior MI
[14]
TARGET
2001
n = 5308
Abciximab vs. tirofiban in patients 
receiving PCI and stenting
Superiority of abciximab with decreased 30 day 
mortality, MI or revascularisation vs tirofiban
More significant thrombocytopaenia with abciximab 
than tirofiban with associated increase in bleeding
[19]
continues >
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ISAR-REACT 2
2006
n = 2022
Abciximab vs. placebo in NSTEMI 
undergoing PCI with dual 
antiplatelet therapy on board
Significant reduction in 30 day mortality, MI or 
revascularisation with abciximab in patients with an 
elevated troponin level
No significant difference in bleeding
[29]
EVA-AMI
2010
n = 427
Eptifibatide vs abciximab therapy 
in STEMI planned for PCI
Non-inferiority of eptifibatide compared to 
abciximab with regards to ST segment resolution
[38]
HORIZONS-
AMI
2008
n = 3602
Bivalirudin vs. heparin and GP 
IIb/IIIa inhibitor (abciximab 
or eptifibatide) in STEMI 
receiving PCI
Significantly less major bleeding and mortality at 30 
days with the use of bivalirudin
[41,43,44,45]
REPLACE-2
2003
n = 6010 
Bivalirudin with provisional GP IIb/
IIIa inhibitor vs. low-dose UFH and 
GP IIb/IIIa inhibitor in urgent or 
elective PCI
Bivalirudin proved superior to heparin alone in 
primary endpoints of mortality
Less bleeding with bivalirudin and provisional GP 
IIb/IIIa inhibitor
Non-inferiority of bivalirudin vs. UFH & GP IIb/IIIa 
inhibitor
[47]
AIDA STEMI
2012
n = 2065
Intracoronary vs intravenous 
abciximab in STEMI
No statistical difference in primary end point of 
death or MI
[50]
Table I. Findings of the main studies
Current guidelines for the use 
of glycoprotein IIb/IIIa inhibitors
ACC/AHA 2009 updated guidelines for STEMI
The focused update of the ACC/AHA guidelines for management of STEMI from 2004 [51] acknowled-
ged the lack of data with regards to the ongoing use of GP IIb/IIIa inhibitors with dual oral antiplatelet 
therapy and also newer anticoagulants such as bivalirudin. It was concluded that the role of GP IIb/IIIa 
inhibitors in current management needs further investigation and admitted the difficulty in drawing 
definitive conclusions with regards to their ongoing role in the management of STEMI.
The ACC/AHA guidelines state that treatment with abciximab (level of evidence: A) at the time of 
primary PCI in selected patients with STEMI is reasonable regardless of whether stent insertion is 
performed. This was classified as a Class IIa recommendation.
These guidelines go on to say that benefit in the use of GP IIb/IIIa inhibitors prior to cardiac cathe-
terisation laboratory remains uncertain due to the lack of supporting evidence (level of evidence: B, 
class IIb).
ESC guidelines for STEMI 2012
Due to the recent prominence of direct thrombin inhibitor use in European centres the updated ESC 
guidelines heavily featured bivalirudin in the management of STEMI with subsequent further down-
grading of the role of GP IIb/IIIa inhibitors [52]. A significant change was the class 1c recommendation 
that an injectable anticoagulant must be used during STEMI and that bivalirudin is now indicated over 
the combination use of heparin and GP IIb/IIIa inhibitor. This recommendation was based on the 
aforementioned recent data showing non-inferiority of bivalirudin and decreased rates of significant 
bleeding and mortality.
> follows
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GP IIb/IIIa inhibitors remain a therapeutic option to be considered for bailout therapy if there should 
be angiographic evidence of massive thrombus, slow or no-reflow or a thrombotic complication (IIa, 
level of evidence: C). It is stated that this indication is only as a recommendation as little data is availa-
ble for this specific use and there is need for further randomised control studies.
Upstream use of GP IIb/IIIa inhibitors was only recommended for consideration in high-risk patients 
as bridging therapy towards primary PCI (IIb, level of evidence: B).
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention
The guidelines from the Society for Cardiovascular Angiography and Interventions (SCAI) have detai-
led accounts of the efficacy and usefulness of GP IIb/IIIa inhibitors not only in STEMI but also unstable 
angina (UA), NSTEMI and stable ischaemic heart disease [53].
Their recommendations are summarized in Table II.
Conclusion
Abciximab is a glycoprotein IIb/IIIa inhibitor with numerous early trials that demonstrated its signifi-
cant efficacy in the treatment of STEMI, NSTEMI and unstable angina. Its use has been proven bene-
ficial in the setting of coronary intervention. It is a potent antiplatelet agent that is capable of complete 
inhibition of platelet aggregation. Its use carries an increased risk of bleeding but if used with caution 
in carefully selected patient groups this risk could be kept very low.
A common and potentially dangerous complication of abciximab therapy is drug-induced throm-
bocytopaenia, which may lead to significant adverse outcomes.
Data suggests the best time of administration is at the time of PCI and there is no clear benefit of admi-
nistration via the intracoronary route or in conjunction with thrombolysis. Abciximab should be used 
in caution in patients that may be candidates for emergency CABG.
Recommendations
STEMI  • Class IIa: GP IIb/IIIa inhibitors are reasonable for use in PCI with unfractionated heparin whether 
the patient has received pre-treatment with clopidogrel (Level of evidence: B) or no dual antiplatelet 
therapy (Level of evidence: A)
 • Class IIb: It is reasonable to use intracoronary abciximab during PCI though not specifically 
recommended (Level of evidence: B)
 • Class III: Routine use of upstream GP IIb/IIIa inhibitors (i.e. prior to cardiac catheter laboratory) is not 
beneficial (Level of evidence: B)
UA/NSTEMI  • Class I: GP IIb/IIIa inhibitors are useful in conjunction with unfractionated heparin in those patients 
undergoing PCI with high risk features (e.g. elevated troponin level) that have not received bivalirudin 
or adequately pre-treated with clopidogrel (Level of evidence: A)
 • Class IIa: GP IIb/IIIa inhibitors are reasonable at the time of PCI in UA/NSTEMI patients with high risk 
features who have been adequately pre-treated with clopidogrel (Level of evidence: B)
Stable IHD  • Class IIa: GP IIb/IIIa inhibitors are reasonable for use during PCI in conjunction with unfractionated 
heparin in those patients not pre-treated with clopidogrel (Level of evidence: B)
 • Class IIb: In patients receiving elective PCI with stent insertion the use of GP IIb/IIIa inhibitors might 
be reasonable in conjunction with unfractionated heparin and pre-treatment with clopidogrel (Level 
of evidence: B)
Table II. Recomendandations of current guidelines
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Early trials in its use pre-date the advent of dual 
oral antiplatelet therapy with aspirin and a thie-
nopyridine agent and thus abciximab and its 
fellow GP IIb/IIIa inhibitors now have a scaled 
down role in current guidelines due to the lack 
of evidence for additional benefit with these 
agents. With the introduction of new anticoagu-
lant agents with improved safety profiles (such 
as bivalirudin) we may soon see further relega-
tion of these drugs to use as bailout therapy with 
PCI only.
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